Aliakbar Mobasseri

Title: Innovator Aliakbar Mobasseri: Advancements in Therapeutic Proteins

Introduction: Aliakbar Mobasseri, an accomplished inventor based in Voorhees, NJ, has made significant contributions to the field of biotechnology through his innovative research and patents. With a focus on enhancing the production of therapeutic proteins, he holds two patents that encapsulate his expertise and vision.

Latest Patents: Mobasseri's latest patents include groundbreaking methods for the expression of soluble therapeutic proteins. His first patent details advances in producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony-stimulating factor (G-CSF), and glucocerebrosidase proteins in microorganisms within an oxidizing environment. His second patent focuses on modified sialyltransferase proteins that demonstrate enhanced expression compared to their unmodified counterparts. This patent also encompasses nucleic acids encoding these proteins, along with methods for their production and application.

Career Highlights: Throughout his career, Mobasseri has collaborated with prominent companies in the biotechnology sector, such as Novo Nordisk A/S and Biogenerix AG. His work emphasizes the importance of innovation in therapeutic protein production, and his patents stand as a testament to his contributions to the field.

Collaborations: Mobasseri has worked alongside notable colleagues, including Karl Frank Johnson and Marc F Schwartz. These collaborations have fostered a rich environment for innovation and have greatly influenced the research outcomes that Mobasseri has achieved.

Conclusion: Aliakbar Mobasseri's work reflects a commitment to advancing biotechnological methods for producing vital therapeutic proteins. His patents not only contribute to scientific knowledge but also pave the way for improvements in medical treatments, thereby enhancing patient care and outcomes.